Interim – Alligator Bioscience

2025-04-24

Regulatory

Alligator Bioscience AB reports financial results for Q1 2025 and provides a business update

24-month data from OPTIMIZE-1 show 29.4% survival rate for mitazalimab—three times higher than chemotherapy alone FDA alignment secure ...

2025-01-22

Regulatory

Sharpened focus on mitazalimab and cost-reduction program to maximize long-term value creation Announcement of rights issue of units of appr ...

2024-10-24

Regulatory

Recruitment completed of 450 µg/kg back-fill cohort in the mitazalimab OPTIMIZE-1 study in pancreatic cancer Positive interim Phase 1 ...

2024-07-112024-07-11

Regulatory

Substantial overall survival benefit and unprecedented Duration of Response reported in 18-month analysis from mitazalimab OPTIMIZE-1 Phase ...

2024-05-06

Regulatory

Mitazalimab Phase 3 preparations underway following positive top-line results from OPTIMIZE-1 Phase 2 study in pancreatic cancer Positive in ...

2024-02-082024-02-14

Regulatory

Mitazalimab meets OPTIMIZE-1 Phase 2 primary endpoint, demonstrating 40.4% Overall Response Rate and median Overall Survival of 14.3 months ...

2023-10-26

Regulatory

European Medicines Agency grants mitazalimab Orphan Designation in pancreatic cancer Technical Feasibility achieved in second collaboration ...

2023-07-13

Regulatory

Positive second interim analysis from OPTIMIZE-1 Phase 2 study shows increase in ORR* and favorable DoR** suggesting durable benefits of mit ...

2023-04-25

Mitazalimab OPTIMIZE-1 Phase 2 trial in pancreatic cancer completes enrolment following positive interim results; top-line data due Q1 2024 ...